(Q43470111)

23 November 2017

Raltegravir resistance in the cerebrospinal fluid (English)

1 reference

23 November 2017

0 references

1 reference

B Mora-Peris

1

1 reference

23 November 2017

N E Mackie

2

1 reference

23 November 2017

D Suan

3

1 reference

23 November 2017

D A Cooper

4

1 reference

23 November 2017

B J Brew

5

1 reference

23 November 2017

A Winston

6

1 reference

23 November 2017

3 February 2013

1 reference

23 November 2017

1 reference

23 November 2017

41

1 reference

23 November 2017

3

1 reference

23 November 2017

731-734

1 reference

https://scigraph.springernature.com/pub.10.1007/s15010-013-0409-z

23 November 2017

0 references

cites work

Evidence for independent development of resistance to HIV-1 reverse transcriptase inhibitors in the cerebrospinal fluid.

1 reference

https://api.crossref.org/works/10.1007%2FS15010-013-0409-Z

Emergence of raltegravir-resistant HIV-1 in the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS15010-013-0409-Z

Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS15010-013-0409-Z

Factors influencing virological response to antiretroviral drugs in cerebrospinal fluid of advanced HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS15010-013-0409-Z

Factors influencing cerebrospinal fluid and plasma HIV-1 RNA detection rate in patients with and without opportunistic neurological disease during the HAART era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS15010-013-0409-Z

HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS15010-013-0409-Z

Cerebrospinal fluid human immunodeficiency virus viral load in patients with neurosyphilis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS15010-013-0409-Z

Antiretroviral treatment effect on immune activation reduces cerebrospinal fluid HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS15010-013-0409-Z

HIV-1 chemokine coreceptor utilization in paired cerebrospinal fluid and plasma samples: a survey of subjects with viremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS15010-013-0409-Z

Raltegravir cerebrospinal fluid concentrations in HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS15010-013-0409-Z

Factors associated with cerebrospinal fluid HIV RNA in HIV infected subjects undergoing lumbar puncture examination in a clinical setting

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23378293

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

HIV genetic diversity between plasma and cerebrospinal fluid in patients with HIV encephalitis

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23378293

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S15010-013-0409-Z

1 reference

23 November 2017

1 reference